Disrupting the Brain
Cancer Space

At Reglagene, we are mission-driven and determined to bring safe, efficacious therapeutic agents for life-threatening brain cancer to market. With funding from Tucson's Desert Angels, Cancer Fund, and Viva BioInnovator, and supplemental grant funding from the National Institutes of Health, we aim to bring our medicines into the clinic posthaste.

Screen Shot 2022-01-13 at 4.51.21 PM.png

Reglagene's Lead Program Is High-Grade Glioma

IND studies are taking place in our High-Grade Glioma program. This clinical candidate is effective in multiple different patient-derived cell lines, has excellent blood–brain barrier penetration, and can be dosed in mice at up to 200 mg/kg/day for extended time intervals without any significant toxicity.


Thanks! Message sent.

3320 N. Campbell Ave Ste 200  |  Tucson,  AZ  85719  |   USA